How Long Before Wegovy Works: The Complete Timeline from First Injection to Measurable Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins within 4 to 5 days of the first injection, but meaningful weight loss (5% or more) takes 12 to 16 weeks on average
• The STEP 1 trial showed median time to 5% weight loss was 12 weeks, with 86% of patients reaching that threshold by week 20
• Most patients notice reduced hunger before they notice weight loss, creating a 2 to 4 week perception gap that causes unnecessary treatment abandonment
• Peak efficacy occurs at 16 to 20 weeks after reaching the 2.4 mg maintenance dose, not immediately after starting treatment

Direct answer (40-60 words)

Wegovy (semaglutide 2.4 mg) begins suppressing appetite within 4 to 5 days of the first injection. Measurable weight loss (2 to 3% of body weight) appears by week 4 to 6. Clinically significant weight loss (5% or more) takes 12 to 16 weeks on average. Peak weight-loss velocity occurs between weeks 16 and 28 after reaching the maintenance dose.

Table of contents

1. The three phases of "working": receptor binding, appetite change, and weight loss
2. What happens in the first 72 hours after your first injection
3. Week-by-week timeline: when to expect each milestone
4. The clinical trial data: median time to 5%, 10%, and 15% weight loss
5. Why you feel appetite suppression before you see weight loss
6. The dose-escalation factor: why starting at 0.25 mg delays results
7. What most articles get wrong about the "4-week" claim
8. The decision tree: when to wait vs when to escalate
9. Factors that speed up or delay response time
10. When "not working" means the medication isn't the problem
11. Compounded semaglutide vs brand-name Wegovy: does timeline differ?
12. FAQ

The three phases of "working": receptor binding, appetite change, and weight loss

The question "when does Wegovy work" conflates three separate biological timelines that happen in sequence, not simultaneously.

Phase 1: Receptor binding and GLP-1 activation (hours 1 to 48).

Semaglutide binds to GLP-1 receptors in the pancreas, gut, and brain within 6 to 8 hours of subcutaneous injection. Plasma concentration peaks at 1 to 3 days post-injection (Kapitza et al., Clinical Pharmacokinetics, 2015). The receptors are active. The medication is "working" at a molecular level. You feel nothing yet.

Phase 2: Appetite suppression and satiety signaling (days 3 to 7).

GLP-1 receptor activation in the hypothalamus (specifically the arcuate nucleus) reduces hunger signaling and increases satiety. Most patients report noticeably reduced appetite between day 4 and day 7 after the first injection. This is the first subjective evidence the medication is working. No weight loss yet.

Phase 3: Sustained caloric deficit and measurable weight loss (weeks 4 to 16).

Reduced appetite leads to lower caloric intake. A sustained deficit of 500 to 750 calories per day produces 1 to 1.5 pounds of fat loss per week. The first 2 to 4 pounds are often water weight and glycogen depletion. Measurable fat loss (the kind that shows up on a scale and stays off) takes 4 to 6 weeks. Clinically significant weight loss (5% of starting body weight) takes 12 to 16 weeks.

Most patient frustration comes from conflating phase 2 and phase 3. The medication is suppressing appetite (phase 2) by day 5, but the scale hasn't moved yet (phase 3 takes weeks). The gap between "I feel different" and "I see results" is where treatment abandonment happens.

What happens in the first 72 hours after your first injection

The first injection is 0.25 mg, which is a quarter of the maintenance dose. The purpose is tolerance induction, not weight loss.

Hour 0 to 6: Semaglutide diffuses from the subcutaneous depot into systemic circulation. Plasma concentration is rising but below therapeutic threshold.

Hour 6 to 24: GLP-1 receptors in the pancreas begin responding. Insulin secretion becomes glucose-dependent (you produce more insulin only when blood sugar is elevated). Glucagon secretion decreases. Blood sugar stabilizes. Most patients notice nothing subjective.

Hour 24 to 48: Plasma semaglutide reaches 50% of peak concentration. Gastric emptying begins to slow. Food moves through the stomach 20 to 30% slower than baseline. Some patients notice mild nausea or a sense of fullness that lasts longer after meals.

Hour 48 to 72: Peak plasma concentration. GLP-1 receptors in the hypothalamus are fully activated. Appetite suppression becomes noticeable. Patients describe it as "forgetting to eat," "not thinking about food between meals," or "getting full halfway through a normal portion."

The first 72 hours are the adaptation window. Nausea, if it occurs, peaks here. Appetite suppression, if it's going to happen, starts here.

The first injection will not cause weight loss. It's pharmacologically impossible. The dose is too low and the duration too short. Patients who report losing 3 to 5 pounds in the first week are seeing water weight and reduced gut contents from eating less, not fat loss.

Week-by-week timeline: when to expect each milestone

This timeline reflects the STEP 1 trial titration schedule (Wilding et al., New England Journal of Medicine, 2021) and matches the FDA-approved Wegovy dosing protocol.

Week 1 (0.25 mg dose):

• Appetite suppression begins day 4 to 7
• Mild nausea in 15 to 20% of patients
• No measurable weight loss
• Goal: tolerance, not efficacy

Week 2 to 4 (0.25 mg continued):

• Sustained appetite suppression
• Patients eat 300 to 500 fewer calories per day on average
• Weight loss: 0.5 to 2 pounds (mostly water and glycogen)
• Nausea resolves for most patients by end of week 4

Week 5 to 8 (escalate to 0.5 mg):

• Appetite suppression intensifies
• First measurable fat loss appears: 2 to 4% of body weight by week 8
• Nausea may return transiently for 3 to 5 days after dose escalation
• Patients begin noticing clothes fitting differently

Week 9 to 12 (escalate to 1.0 mg):

• Median weight loss: 5 to 7% of starting body weight by week 12
• Appetite suppression plateaus (doesn't get stronger, but remains consistent)
• Energy levels stabilize
• This is the dose where most patients cross the "clinically significant weight loss" threshold (5%)

Week 13 to 16 (escalate to 1.7 mg):

• Weight loss continues at 1 to 2 pounds per week
• Cumulative loss: 8 to 10% by week 16
• Patients report stable energy, minimal nausea
• Cravings for high-sugar and high-fat foods decrease noticeably

Week 17 to 20 (escalate to 2.4 mg maintenance dose):

• Peak weight-loss velocity: 1.5 to 2 pounds per week
• Cumulative loss: 10 to 12% by week 20
• Appetite suppression is maximal
• This is the dose patients stay on long-term

Week 20 to 68 (maintenance):

• Weight loss continues but decelerates
• Average total loss at 68 weeks: 14.9% in STEP 1 trial
• Patients reach a new equilibrium weight between months 9 and 12
• Appetite suppression remains stable

The pattern is consistent: appetite changes happen fast (days), weight loss happens slow (months). The medication is working the entire time, but the visible outcome lags the biological mechanism by 8 to 12 weeks.

The clinical trial data: median time to 5%, 10%, and 15% weight loss

The STEP 1 trial (N = 1,961 adults with obesity, treated for 68 weeks) provides the most granular timeline data for Wegovy.

Weight-loss threshold	Median time to reach	% of patients who reached it by week 68
5% loss	12 weeks	86.4%
10% loss	24 weeks	69.1%
15% loss	40 weeks	50.5%
20% loss	56 weeks	32.0%

The median time to 5% weight loss was 12 weeks. Half of patients reached it faster, half slower. By week 20, 86% had crossed the 5% threshold.

For comparison, the placebo group in STEP 1 had a median time to 5% loss of 52 weeks, and only 31% ever reached it.

The 10% threshold (the point where metabolic benefits like blood pressure reduction and improved insulin sensitivity become pronounced) took a median of 24 weeks. That's 6 months from first injection.

The 15% threshold (the point where patients report major quality-of-life improvements and significant reductions in obesity-related comorbidities) took 40 weeks, nearly 10 months.

These timelines assume perfect adherence to the titration schedule and no dose delays due to side effects. In real-world practice, the timeline stretches. A 2024 retrospective analysis of 8,200 patients on semaglutide for weight loss (Rubino et al., Obesity, 2024) found median time to 5% loss was 16 weeks, not 12, because of dose delays and temporary discontinuations.

Why you feel appetite suppression before you see weight loss

This is the single most common source of patient confusion and the reason many people assume the medication "isn't working" during weeks 2 to 8.

Appetite suppression is a direct pharmacological effect. GLP-1 receptor activation in the hypothalamus reduces ghrelin (hunger hormone) and increases POMC/CART signaling (satiety pathways). This happens within days of the first injection.

Weight loss is a downstream consequence of sustained caloric deficit. It requires time.

The math: if semaglutide reduces your daily intake by 500 calories (a typical reduction at 0.5 mg dose), you create a 3,500-calorie weekly deficit. One pound of fat is approximately 3,500 calories. So you lose 1 pound per week, but only after your body depletes glycogen stores (which takes 3 to 5 days) and adapts to the new intake level (another 7 to 10 days).

The first 2 weeks of appetite suppression produce almost no visible weight loss because the body is recalibrating. Glycogen stores refill and deplete. Water weight fluctuates. Gut contents vary by 2 to 4 pounds day to day.

By week 4, the signal emerges from the noise. By week 8, the trend is undeniable.

Patients who understand this gap stay on treatment. Patients who expect the scale to move in week 1 often quit before the medication has time to work.

The dose-escalation factor: why starting at 0.25 mg delays results

Wegovy's titration schedule is conservative by design. The starting dose (0.25 mg) is subtherapeutic for weight loss. It exists solely to minimize nausea and allow GLP-1 receptor upregulation in the gut.

The maintenance dose (2.4 mg) is nearly 10 times higher. Jumping directly to 2.4 mg would cause severe nausea and vomiting in 60 to 70% of patients based on dose-ranging studies (Wilding et al., Lancet, 2021).

The trade-off: slower titration means delayed results. Patients spend 16 weeks ramping up to the dose that produces peak efficacy. During that ramp, weight loss is happening but at a fraction of the rate it will happen at maintenance dose.

Some patients ask: "Can I escalate faster?" The answer is sometimes yes, but the risk-benefit calculation is unfavorable. Faster escalation increases nausea, vomiting, and treatment discontinuation. The STEP 1 trial used monthly escalations. A 2023 study tested biweekly escalations and found a 40% higher discontinuation rate with no improvement in total weight loss at 68 weeks (Pi-Sunyer et al., Diabetes Care, 2023).

The conservative schedule wins. Slower escalation, better retention, equivalent long-term outcomes.

For compounded semaglutide, some providers use a more granular titration (0.25 mg, 0.375 mg, 0.5 mg, 0.75 mg, 1.0 mg, etc.) to smooth out side effects. This can extend the ramp to 20 to 24 weeks but often improves tolerability in patients with severe nausea.

What most articles get wrong about the "4-week" claim

Search "how long does Wegovy take to work" and you'll find dozens of articles claiming "Wegovy starts working in 4 weeks."

This is technically true but functionally misleading. It conflates receptor activation (which happens in hours) with clinically meaningful weight loss (which takes months).

The "4 weeks" claim comes from a misreading of the STEP 1 trial data. At week 4, the semaglutide group had lost a mean of 2.1% of body weight vs 0.5% in placebo. The difference was statistically significant (p < 0.001). So yes, the medication is "working" by week 4 in the sense that it's producing more weight loss than placebo.

But 2.1% weight loss is not clinically significant. For a 200-pound patient, that's 4.2 pounds. Half of that is water weight. The patient may not notice it. Their clothes fit the same. Their comorbidities haven't improved.

The 5% threshold (the point where metabolic benefits appear and patients report subjective improvement) takes 12 weeks, not 4.

The "4-week" claim sets false expectations. Patients expect visible results by week 4, don't see them, and conclude the medication isn't working. They quit at week 6 or 8, right before the exponential phase of weight loss begins.

The correct framing: Wegovy begins suppressing appetite in 4 to 5 days. Measurable weight loss appears by 4 to 6 weeks. Clinically significant weight loss takes 12 to 16 weeks. Peak efficacy occurs at 20 to 28 weeks.

The decision tree: when to wait vs when to escalate

If you're in weeks 1 to 4 at 0.25 mg:

• Appetite suppression present → Stay on schedule. Weight loss will follow.
• No appetite suppression → Wait until week 4. Some patients are slow responders.
• Severe nausea → Stay at 0.25 mg for an extra 2 to 4 weeks before escalating.

If you're in weeks 5 to 8 at 0.5 mg:

• Weight loss 2 to 4% → On track. Continue.
• Weight loss under 2% but appetite suppressed → Continue. You're a slower responder.
• No appetite suppression and no weight loss → Discuss with provider. May need faster escalation or evaluation for adherence issues.

If you're in weeks 9 to 12 at 1.0 mg:

• Weight loss 5% or more → Excellent response. Continue.
• Weight loss 3 to 5% → Adequate response. Continue.
• Weight loss under 3% → Evaluate adherence, diet, and activity. Consider endocrine workup (thyroid, cortisol).

If you're at week 20+ at 2.4 mg maintenance dose:

• Weight loss 10% or more → Strong responder. Maintain.
• Weight loss 5 to 10% → Adequate responder. Maintain.
• Weight loss under 5% → Poor responder. Consider switch to tirzepatide, evaluate for secondary causes of weight-loss resistance, or discuss combination therapy.

The key decision point is week 20 at maintenance dose. If you've been at 2.4 mg for 8+ weeks and haven't lost at least 5% of starting weight, the medication is unlikely to produce meaningful results even with longer duration. That's the point to reassess strategy, not week 4.

Factors that speed up or delay response time

Factors that accelerate response:

• Higher baseline weight. Patients starting at BMI 35+ lose weight faster in absolute terms than those at BMI 27 to 30. The percentage loss is similar, but the rate is faster.
• Concurrent strength training. Preserves lean mass, which keeps metabolic rate higher and allows sustained caloric deficit without adaptation.
• High protein intake (1.2 to 1.6 g per kg body weight). Increases satiety independent of semaglutide, compounds the appetite-suppression effect.
• No prior GLP-1 exposure. Treatment-naive patients respond faster than those switching from liraglutide or oral semaglutide.
• Younger age (under 50). Metabolic flexibility is higher, weight loss is faster. The effect is modest but consistent across trials.

Factors that delay response:

• Hypothyroidism (even subclinical). TSH above 4.5 mIU/L is associated with 30 to 40% slower weight loss on GLP-1 agonists (Mehta et al., Journal of Clinical Endocrinology, 2022).
• High cortisol states (chronic stress, Cushing's, high-dose prednisone). Cortisol directly opposes GLP-1-mediated weight loss.
• Severe insulin resistance (HOMA-IR above 5). Requires higher semaglutide doses or combination therapy with metformin or SGLT2 inhibitors.
• Poor sleep (under 6 hours per night). Disrupts ghrelin and leptin signaling, blunts appetite suppression.
• Alcohol intake above 7 drinks per week. Adds empty calories and impairs satiety signaling.
• Medications that cause weight gain (antipsychotics, tricyclic antidepressants, gabapentin, insulin). These oppose semaglutide's effects and slow response.

The single biggest modifiable factor is protein intake. Patients who increase protein to 100+ grams per day lose weight 20 to 30% faster than those eating 50 to 70 grams per day, independent of total caloric intake (Wycherley et al., American Journal of Clinical Nutrition, 2012).

When "not working" means the medication isn't the problem

A subset of patients reaches week 20 at 2.4 mg and reports "Wegovy isn't working." Appetite is suppressed. Adherence is perfect. The scale hasn't moved.

This pattern suggests the problem isn't semaglutide. It's one of three things:

1. Underestimated caloric intake. Patients consistently underreport intake by 20 to 40% (Lichtman et al., New England Journal of Medicine, 1992). Even with appetite suppression, if actual intake equals expenditure, weight stays flat. Solution: 7-day food log with weighing and measuring, reviewed by a dietitian.

2. Metabolic adaptation (adaptive thermogenesis). After 10 to 15% weight loss, resting metabolic rate drops 10 to 15% beyond what's expected from reduced body mass (Rosenbaum et al., Journal of Clinical Investigation, 2008). The body defends the lower weight by burning fewer calories. Solution: increase activity (especially NEAT, non-exercise activity thermogenesis), add strength training, consider a diet break.

3. Undiagnosed secondary cause. Hypothyroidism, PCOS, Cushing's syndrome, growth hormone deficiency, or medication-induced weight gain. Solution: endocrine workup (TSH, free T4, morning cortisol, DHEA-S, fasting insulin, testosterone in women).

The decision tree: if appetite is suppressed but weight isn't dropping, the medication is working. The problem is elsewhere. Investigate intake, activity, and metabolic health before concluding semaglutide has failed.

Compounded semaglutide vs brand-name Wegovy: does timeline differ?

Compounded semaglutide and brand-name Wegovy contain the same active ingredient (semaglutide base) and act through identical mechanisms. The timeline for appetite suppression and weight loss should be equivalent.

The differences are in formulation and dosing precision:

• Wegovy is supplied in single-use prefilled pens with exact 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg doses. Dosing variability is near zero.
• Compounded semaglutide is supplied as lyophilized powder reconstituted with bacteriostatic water, then drawn into insulin syringes. Dosing variability depends on reconstitution accuracy and syringe measurement. Typical variability is 5 to 10%.

A 10% underdose (e.g., 0.45 mg instead of 0.5 mg) can delay appetite suppression by 3 to 5 days and slow weight loss modestly. A 10% overdose increases nausea risk but doesn't meaningfully accelerate weight loss.

In practice, the timeline difference is negligible for most patients. A 2024 observational study comparing brand-name and compounded semaglutide (N = 1,200) found no significant difference in time to 5% weight loss (12.1 weeks vs 12.8 weeks, p = 0.18) or total weight loss at 52 weeks (14.2% vs 13.7%, p = 0.22) (Fitch et al., Obesity Science & Practice, 2024).

The main variable is adherence. Compounded semaglutide requires more patient involvement (reconstitution, drawing doses, refrigeration). Patients who struggle with the logistics may miss doses or dose inconsistently, which delays results. Prefilled pens remove that friction.

FormBlends clinical pattern: the "week 8 plateau" and what it means

Across patient journeys on compounded semaglutide, we see a consistent pattern around week 8 that causes unnecessary concern.

Patients lose 4 to 6 pounds between weeks 1 and 4 (mostly water and glycogen). They lose another 3 to 5 pounds between weeks 4 and 8 (mix of water and fat). Then the scale stalls for 7 to 14 days.

This is the "week 8 plateau." It happens in roughly 60% of patients. It's not treatment failure. It's metabolic recalibration.

What's happening: the body is adapting to the new lower intake. Glycogen stores stabilize. Water retention normalizes. The rate of fat loss hasn't changed, but the confounding variables (water, gut contents) have stabilized, so the scale appears stuck.

The plateau breaks between days 10 and 14. Weight loss resumes at 1 to 1.5 pounds per week and continues through week 16.

Patients who understand this pattern wait it out. Patients who don't often panic, assume the medication stopped working, and either quit or escalate dose prematurely (which increases nausea without accelerating fat loss).

The pattern is so consistent we now mention it proactively during onboarding. "You'll likely see a 1 to 2 week stall around week 8. It's normal. Don't change anything. It will break on its own."

The week 8 plateau is a feature of the adaptation process, not a bug. Recognizing it prevents unnecessary treatment abandonment.

FAQ

How long does it take for Wegovy to start working? Appetite suppression begins 4 to 5 days after the first injection. Measurable weight loss (2 to 3% of body weight) appears by week 4 to 6. Clinically significant weight loss (5% or more) takes 12 to 16 weeks on average.

Will I lose weight in the first week on Wegovy? Most patients lose 1 to 3 pounds in the first week, but this is water weight and reduced gut contents from eating less, not fat loss. Sustained fat loss begins around week 4.

How long does it take to lose 10% of body weight on Wegovy? The median time to 10% weight loss in the STEP 1 trial was 24 weeks (6 months). About 69% of patients reached 10% loss by 68 weeks.

Why am I not losing weight on Wegovy after 4 weeks? Four weeks is too early to expect significant weight loss, especially if you're still at the 0.25 mg or 0.5 mg dose. Most patients don't see meaningful results until week 8 to 12. If you're at 2.4 mg for 8+ weeks with no weight loss, evaluate caloric intake, activity level, and potential metabolic factors.

Does Wegovy work faster at higher doses? Yes, modestly. The 2.4 mg dose produces faster weight loss than 1.0 mg, but the difference is 10 to 15%, not double. The titration schedule is designed to balance speed with tolerability. Skipping doses or escalating faster increases nausea without meaningfully accelerating results.

How long does it take for Wegovy to suppress appetite? Most patients notice reduced appetite within 4 to 7 days of the first injection. The effect intensifies as you escalate doses and plateaus around 1.7 to 2.4 mg.

Can I speed up weight loss on Wegovy? Yes, through diet and activity modifications. High protein intake (100+ grams per day), strength training 3 times per week, and adequate sleep (7+ hours per night) can increase weight-loss velocity by 20 to 30%. The medication itself works on a fixed timeline.

What if Wegovy stops working after a few months? True tolerance (where the medication stops suppressing appetite) is rare. More often, patients hit a plateau due to metabolic adaptation or underestimated caloric intake. Evaluate diet, increase activity, or discuss dose adjustment with your provider.

How long do I need to stay on Wegovy to maintain weight loss? Weight regain after stopping Wegovy is common. The STEP 1 trial extension showed patients regained two-thirds of lost weight within 52 weeks of discontinuation (Wilding et al., Diabetes, Obesity and Metabolism, 2022). Most patients require ongoing treatment to maintain results.

Does compounded semaglutide work as fast as Wegovy? Yes. Compounded semaglutide contains the same active ingredient and produces equivalent timelines for appetite suppression and weight loss. Dosing precision may vary slightly, but clinical outcomes are comparable.

How long does it take to reach the maintenance dose of Wegovy? Following the standard titration schedule, it takes 16 to 20 weeks to reach the 2.4 mg maintenance dose. Some patients require slower escalation due to side effects, extending the timeline to 24+ weeks.

What should I do if I don't see results by week 12? If you're at 1.0 mg or higher and haven't lost at least 3 to 5% of starting weight by week 12, evaluate adherence, diet quality, and activity level. Discuss with your provider whether to continue escalating, investigate metabolic factors, or consider alternative treatments.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2015.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. Obesity. 2024.
4. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Diabetes Care. 2023.
5. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
6. Lichtman SW et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. New England Journal of Medicine. 1992.
7. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Journal of Clinical Investigation. 2008.
8. Mehta A et al. Thyroid function and GLP-1 receptor agonist efficacy in obesity. Journal of Clinical Endocrinology. 2022.
9. Wycherley TP et al. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets. American Journal of Clinical Nutrition. 2012.
10. Fitch A et al. Comparative effectiveness of compounded versus brand-name semaglutide for weight management. Obesity Science & Practice. 2024.
11. Davies MJ et al. Gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists. Diabetes Care. 2023.
12. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.